U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846736) titled 'ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study' on Feb. 20.
Brief Summary: The Goal of this observational study is to develop an AI-driven pathologic image analysis-based classifier that can identify patients unlikely to significantly benefit from the currently utilized first-line ALK inhibitors (advanced-generation ALK inhibitors). Our goal is a classifier with final ROC-AUC value of 0.75.
Study Start Date: Aug. 13, 2023
Study Type: OBSERVATIONAL
Condition:
Alk-positive Non-Small Cell Lung Cancer
ALK-inhibitor Treated
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Sheba Medical Center...